NCT04487886View on ClinicalTrials.gov

Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

June 10, 2021

Study Completion Date

June 10, 2021

Conditions
COVID-19
Interventions
DRUG

Duvelisib

Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.

DRUG

Placebo

A placebo to match duvelisib will be taken orally twice per day for 14 days.

Trial Locations (3)

30308

Emory Saint Joseph's Hospital, Atlanta

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

Verastem, Inc.

INDUSTRY

lead

Emory University

OTHER

NCT04487886 - Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19) | Biotech Hunter | Biotech Hunter